Compare Gitlab Inc (GTLB) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Novartis AG — how do they compare? Gitlab Inc trades at $41.29 (market cap $7.11B), while Novartis AG trades at $152.75 (market cap $295.37B). The key difference: Novartis AG is far larger — about 41.5× Gitlab Inc's market cap, and Novartis AG pays a 3.07% dividend while Gitlab Inc pays none. Which is the better fit depends on your goals.
| GTLB | NVS | |
|---|---|---|
Market Cap | $7.11B | $295.37B |
Sector | Technology | Health |
52-Week High | $51.04 | $168.62 |
52-Week Low | $19.42 | $119.31 |
Enterprise Value | $5.85B | $336.69B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $40.73, up 4.52% today, with a bullish technical signal from moving averages and a consensus analyst price target of $32.92. Recent earnings beats in Q3 2025 to Q1 2026 highlight strong execution, while revenue grew to $759.25 million in 2025. The stock's high P/E of 521.22 reflects growth expectations, but negative net income and cash flow pose challenges.
Outlook: Growth in DevSecOps and AI-driven software demand supports upside, but profitability risks and high valuation require caution. Key catalysts include continued revenue expansion and path to positive cash flow, while competition and execution missteps are primary risks for investors.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
